Medical Oncology and Hematology Associates-Des Moines Trials

Medical Oncology and Hematology Associates-Des Moines	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Vanderweele, David

ARACOG, NCT04335682: Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Recruiting

132

Darolutamide, Nubeqa, Enzalutamide, Xtandi

Alliance Foundation Trials, LLC., Bayer

Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer

08/24

Lad, Thomas E

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma

01/28

05/35

Wilbur, Deborah

SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting

700

Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806

SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

03/25

03/28

PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting

354

Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac

SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.

Colorectal Neoplasms

02/27

02/32

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

PREDICT, NCT03448926: The Registry for DCIS Patients With DCISionRT Testing

Suspended

N/A

2500

US, RoW

Treatment Recommendation Surveys

PreludeDx, University of South Florida

DCIS

11/25

11/35

MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting

N/A

750

Canada, US

MRD

Exact Sciences Corporation, NSABP Foundation Inc

Colorectal Cancer

02/28

Bryan, Locke J

VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Completed

1/2

US, RoW

VRx-3996, Nanatinostat, Valganciclovir

Viracta Therapeutics, Inc.

Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders

04/23

05/23

MPCT-012L, NCT05826535: Study of IMPT-314 in R/R Aggressive B-cell NHL

Recruiting

1/2

150

IMPT-314

ImmPACT Bio

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma

06/25

12/29

NCT04072458: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Recruiting

L-Bcl-2 antisense oligonucleotide, BP1002

Bio-Path Holdings, Inc.

Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL

09/24

01/26

Hu-Lieskovan, Siwen

NCT05180799: A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors

Recruiting

1/2

320

US, RoW

BA3071, Nivolumab, Pembrolizumab

BioAtla, Inc.

Solid Tumor, Adult, NSCLC, Urothelial Carcinoma, Gastric Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Cervical Carcinoma, Melanoma, Renal Cell Carcinoma, Carcinoma

12/24

06/25

PRESERVE-001, NCT04140526: Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting

1/2

733

US, RoW

ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, Keytruda, MK3475, Docetaxel, Taxotere, Docefrez

OncoC4, Inc., National Cancer Institute (NCI)

Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma

06/26

12/27

CA101-001, NCT04423029 / 2021-000038-33: A Study of DF6002 Alone and in Combination With Nivolumab

Recruiting

1/2

473

Europe, US, RoW

DF6002, Nivolumab, Opdivo

Dragonfly Therapeutics

Solid Tumors

07/24

12/25

NCT05267626: Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting

1/2

136

US, RoW

AU-007, Aldesleukin

Aulos Bioscience, Inc.

Advanced Solid Tumor, Metastatic Cancer

08/25

09/25

KEYNOTE-C82, NCT04648202: FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Recruiting

277

Europe, US

FS120, Pembrolizumab (KEYTRUDA®)

invoX Pharma Limited, Merck Sharp & Dohme LLC

Advanced Cancer, Metastatic Cancer

03/26

Bhatia, Aarti

NCT02979977: Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Recruiting

cetuximab, Erbitux, afatinib, GIOTRIF or GILOTRIF

Yale University, National Comprehensive Cancer Network, Boehringer Ingelheim

Squamous Cell Cancers of the Head and Neck

12/24

01/25

Fusselman, William P

PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting

354

Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac

SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.

Colorectal Neoplasms

02/27

02/32

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI

Recruiting

1100

Canada, US

Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20

SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP

Multiple Myeloma

07/29

07/40

PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting

N/A

2000

Europe, US, RoW

Plasma sample collection

OncoHost Ltd.

Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma

10/29

Drescher, Charles

SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting

700

SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

03/25

03/28

DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI

Recruiting

1100

Canada, US

Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20

SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP

Multiple Myeloma

07/29

07/40

NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting

396

Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T

SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.

Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma

12/25

12/29

NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting

Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy

SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences

Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8

02/25

12/26

SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting

160

Canada, US, RoW

disitamab vedotin, RC48, RC48-ADC

Seagen Inc.

Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms

05/26

05/28

FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting

1/2

210

Europe, US, RoW

CPI-0209

Constellation Pharmaceuticals

Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma

12/25

03/26

Raghavendra, Meghana

AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Recruiting

150

Europe, Canada, Japan, US, RoW

Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A

GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd

Neoplasms, Rectal

11/26

10/29

Bergsland, Emily

NCT05746208: Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Recruiting

Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Hyperpolarized 13C-Pyruvate, HP 13C

University of California, San Francisco, Merck Sharp & Dohme LLC

Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site

07/27

10/27

Qamar, Rubina

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Recruiting

197

Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077

Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research

Breast Cancer, Triple Negative Breast Cancer

01/29

01/34

Lukenbill, Joshua C

SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting

700

SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

03/25

03/28

PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting

354

Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac

SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.

Colorectal Neoplasms

02/27

02/32

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI

Recruiting

1100

Canada, US

Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20

SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP

Multiple Myeloma

07/29

07/40

NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting

186

Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited

CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation

10/24

06/25

Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting

350

Europe, Canada, US

9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar

Actuate Therapeutics Inc.

Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma

11/24

11/25

NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting

Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy

SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences

Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8

02/25

12/26

NCT04566393: Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Available

N/A

Ulixertinib (BVD-523)

xCures, Cancer Commons

Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation

Vasireddy, Vamsi K

BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting

124

Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation

Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation

10/24

Ruggeri, Antony

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting

3791

Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi

American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors

12/24

12/25

Saphner, Thomas J

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

Faller, Bryan

SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting

700

SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

03/25

03/28

PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting

354

Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac

SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.

Colorectal Neoplasms

02/27

02/32

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI

Recruiting

1100

Canada, US

Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20

SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP

Multiple Myeloma

07/29

07/40

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting

124

Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation

Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation

10/24

NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting

Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy

SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences

Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8

02/25

12/26

NCT05798663: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Recruiting

178

Atezolizumab, Tecentriq, L01XC32, Tiragolumab

Alliance Foundation Trials, LLC., Genentech, Inc.

NSCLC

08/25

10/27

MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting

N/A

750

Canada, US

MRD

Exact Sciences Corporation, NSABP Foundation Inc

Colorectal Cancer

02/28

Mantha, Suparna

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting

186

Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited

CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation

10/24

06/25

ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting

122

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080

Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.

Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma

12/24

12/26

NCT03789162: Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Recruiting

N/A

1500

Canada, US

Exact Sciences Corporation

Colorectal Cancer

12/24

Contact, Site Public

NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed

RoW

ADVATE

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Hemophilia A

02/23

SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Completed

Digital Engagement Application (GD App), No Intervention

Takeda

Gaucher Disease

02/23

COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting

200

CDPATH™, PROSPECT, Blood Draw

Takeda

Crohn's Disease

08/23

06/26

NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting

RoW

Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M

Takeda, Takeda

Central Precocious Puberty

05/25

Mucopolysaccharidosis II, NCT05058391: A Study of Elaprase in Children and Adults With Hunter Syndrome () in India

Recruiting

RoW

Elaprase, Idursulfase

Takeda

Hunter Syndrome

08/24

09/24

NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Active, not recruiting

RoW

Brentuximab vedotin, SGN-35

Takeda

T-Cell Lymphoma

09/24

NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India

Active, not recruiting

RoW

Replagal

Shire

Fabry Disease

10/26

11/26

NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting

288

Europe, US

Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo

Shire, Takeda Development Center Americas, Inc.

Attention Deficit Hyperactivity Disorder

06/27

ASPIRE, NCT04118088: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Active, not recruiting

Europe, RoW

Darvadstrocel, Alofisel, Cx601

Takeda, Takeda Development Center Americas, Inc.

Crohn's Disease, Complex Perianal Fistula

03/26

NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting

ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)

Takeda, Takeda Development Center Americas, Inc.

Mucopolysaccharidosis (MPS), Hunter Syndrome

06/27

NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting

150

Canada, US

Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara

Takeda

Crohn's Disease

06/27

NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting

Canada, US

Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550

Takeda

Ulcerative Colitis

07/27

PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

	Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Initiation of new trial in Ph+ ALL
	Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL

Active, not recruiting

245

Europe, Canada, Japan, US, RoW

Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Takeda

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

08/22

07/27

NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated

Europe, Canada

REPLAGAL, SHP675

Shire

Fabry Disease

12/22

NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed

Europe, Canada, Japan, US

Lanadelumab, DX-2930, SHP643, TAK-743

Shire, Takeda Development Center Americas, Inc.

Angioedema

05/23

NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed

Europe, Japan, US

BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Thrombotic Thrombocytopenic Purpura (TTP)

12/23

05/24

NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Recruiting

Europe, US, RoW

rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Von Willebrand Disease (VWD)

03/25

NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed

270

Europe, Canada, Japan, US, RoW

Soticlestat, TAK-935, Placebo

Takeda

Lennox Gastaut Syndrome (LGS)

01/24

NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting

Europe, US

Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo

Takeda

Alpha1-Antitrypsin Deficiency

08/28

NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting

Europe, US, RoW

von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII

Baxalta now part of Shire, Takeda Development Center Americas, Inc.

Von Willebrand Disease

01/25

NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed

144

Europe, Canada, Japan, US, RoW

Soticlestat, TAK-935, Placebo

Takeda

Dravet Syndrome (DS)

04/24

TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Recruiting

Europe

Soticlestat, TAK-935

Takeda

Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)

01/27

NCT04974749: A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

Completed

RoW

REPLAGAL, Agalsidase Alfa, TAK-675

Takeda

Fabry Disease

01/24

NCT05460325: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed

RoW

Lanadelumab, SHP643, TAKHZYRO, TAK-743, DX-2930, Lanadelumab Injection

Takeda

Hereditary Angioedema (HAE)

11/23

Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

Not yet recruiting

Europe, RoW

Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy

Takeda

Pouchitis

12/29

NCT06060067 / 2023-000134-15: A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

Recruiting

480

RoW

TDV, TAK-003, Placebo

Takeda, Takeda

Healthy Volunteers

11/24

04/25

NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting

120

Europe, Canada, Japan, US, RoW

Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002

Takeda, Takeda Development Center Americas, Inc.

Crohn's Disease (CD)

11/24

NCT05529992 / 2022-002323-35: A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Active, not recruiting

RoW

Velaglucerase Alfa, VPRIV

Takeda, Takeda

Gaucher Disease

08/24

NCT05707351: A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Active, not recruiting

RoW

Adynovate, Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol

Takeda

Hemophilia A

10/24

NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Not yet recruiting

RoW

Maribavir, TAK-620

Takeda

Cytomegalovirus (CMV)

02/27

SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting

700

SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

03/25

03/28

NCT04701411 / 2020-003193-48: A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

Recruiting

Europe, Japan, RoW

Darvadstrocel, Cx601

Takeda, Takeda Development Center Americas, Inc.

Crohn's Disease, Complex Perianal Fistula

06/25

12/25

TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Recruiting

1000

Europe, Canada, US

TAK-279, Placebo, Apremilast

Takeda

Plaque Psoriasis

07/25

06/26

NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Recruiting

600

Europe, Canada, Japan, US

TAK-279, Placebo, Apremilast

Takeda

Plaque Psoriasis

08/25

04/26

MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

Recruiting

120

Europe, Canada, Japan, US, RoW

Vedolizumab, MLN0002, ENTYVIO, KYNTELES

Takeda, Takeda Development Center Americas, Inc.

Colitis, Ulcerative

08/25

NCT04759833: A Study of Prucalopride For Functional Constipation in Children and Teenagers

Terminated

175

Prucalopride, TAK-555, Prucalopride succinate, Placebo

Takeda, Takeda Development Center Americas, Inc.

Constipation

11/23

NCT05156983: A Study of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation

Recruiting

328

Europe, Canada, US

TAK-330, SOC 4F-PCC

Takeda, Takeda Development Center Americas, Inc.

Coagulation Disorder

11/25

ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Recruiting

400

Europe, Canada, Japan, US, RoW

Soticlestat, TAK-935

Takeda

Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)

05/26

NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting

Europe, Japan, US, RoW

TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930

Takeda, Takeda Development Center Americas, Inc., Shire

Thrombotic Thrombocytopenic Purpura (TTP)

03/27

NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection

Recruiting

Europe, Japan, US, RoW

Maribavir, TAK-620

Takeda, Takeda Development Center Americas, Inc.

Cytomegalovirus (CMV)

11/26

NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Recruiting

408

RoW

Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine

GC Cell Corporation

Pancreatic Ductal Adenocarcinoma

12/26

06/27

PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting

354

Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac

SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.

Colorectal Neoplasms

02/27

02/32

NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting

160

Europe, Canada, US, RoW

Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride

Takeda, Takeda Development Center Americas, Inc.

Alpha1-Antitrypsin Deficiency

03/27

03/29



	Diseases Companies Products Productz Mechanisms of Action Sites